Use of transgenic mice in identifying chemopreventive agents

Toxicology Letters

Volumn 112-113, Issue , 2000, Pages 507-512

  Alexander, Jan ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Chemoprevention; FAP models; Min mice; NSAID; p53; PIM 1; Transgenic mice

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PROTEIN P53; RETINOID;

ADENOMATOUS POLYP; ANIMAL MODEL; CANCER PREVENTION; CARCINOGENESIS; CELL CYCLE; CHEMOPROPHYLAXIS; CONFERENCE PAPER; CONTROLLED STUDY; DIET; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARCINOGENS; CHEMOPREVENTION; DIET; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0034654276     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(99)00213-1     Document Type: Conference Paper

References (49)

1. Barnes C.J., Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology. 114:1998;873-877.
2. Beazer-Barclay Y., Levy D.B., Moser A.R., Dove W.F., Hamilton S.R., Vogelstein B., Kinzler K.W. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis. 17:1996;1757-1760.
3. Boolbol S.K., Dannenberg A.J., Chadburn A., Martucci C., Jun Guo X., Ramonetti J.T., Abreu-Goris M., Newmark H., Lipkin M.L., DeCosse J.J., Bertagnolli M.M. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindacin a murine model of familial adenomatous polyposis. Cancer Res. 56:1996;2556-2560.
4. Breuer M., Wientjens E., Verbeek S., Slebos R., Berns A. Carcingen-induced lymphomagenesis in pim-1 transgenic mice: dose dependence and involvement of myc and ras. Cancer Res. 51:1991;958-963.
5. Chan T.A., Morin P.J., Vogelstein B., Kinzler K.W. Mechanisms underlying nonsteroid antiinflammatory drug-mediated apoptosis. Proc. Natl. Acad. Sci. USA. 95:1998;681-686.
6. Donehower L.A. The p53-deficient mouse: a model for basic and applied cancer studies. Semin. Cancer Biol. 7:1996;269-278.
7. Fodde R., Khan P.M. Genotype-phenotype correlations at the adenomatous polyposis coli (APC) gene. Crit. Rev. Onogen. 6:1995;291-303.
8. Harvey M., McArthur M.J., Montgomery C.A. Jr, Butel J.S., Bradley A., Donehower L.A. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat. Genet. 5:1993;225-229.
9. Hioki K., Shivapurkar N., Oshima H., Alabaster O., Oshima M., Taketo M.M. Suppression of intestinal polyp development by low-fat and high-fiber diet in APC (delta716) knockout mice. Carcinogenesis. 18:1997;1863-1865.
10. Hursting S.D., Perkins S.N., Haines D.C., Ward J.M., Phang J.M. Chemoprevention of spontaneous tumorigenesis in p53-knockout mice. Cancer Res. 55:1995;3949-3953.
11. Hursting S.D., Perkins S.N., Brown C.C., Haines D.C., Phang J.M. Caloric restriction induces a p53 independent delay of spontaneous carcinogenesis in p53-deficient and wild type mice. Cancer Res. 57:1997;2843-2846.
12. Jacoby R.F., Marshall D.J., Newton M.A., Novakovic K., Tutsch K., Cole C.E., Lubet R.A., Kellof G.J., Verma A., Moser A.R., Dove W.F. Chemoprevention of spontaneous intestinal adenomas in the ApcMin mouse model by nonsteriodal anti-inflammatory drug piroxicam. Cancer Res. 56:1996;710-714.
13. Jen J., Powell S.M., Papadopoulos N., Shibata D., Perucho M. Molecular determinants of dysplasia in colorectal lesions. Cancer Res. 54:1994;5523-5526.
14. Kennedy A.R., Beazer-Barclay Y., Kinzler K.W., Newborne P.M. Suppresssion of carcinogenesis in the intestine of Min mice by the soybean-derived Bowman-Birk inhibitor. Cancer Res. 56:1996;679-682.
15. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 87:1996;159-170.
16. Kroese E.D., Dortant P., van Steeg H., van Oostrom C.Th.M., van der Houvenvan van Oordt C.W., van Kranen H.J., de Vries A., Wester P.W., van Kreijl C.F. Use of Eμ-PIM-1 transgenic mice for short-term in vivo carcinogenicity testing: lymphoma induction by benzo(a)pyrene, but not by TPA. Carcinogenesis. 18:1997;975-980.
17. Levy D.B., Smith K.J., Beazer-Barclay Y., Hamilton S.R., Vogelstein B., Kinzler K.W. Inactivation of both APC alleles in human and mouse tumors. Cancer Res. 54:1994;5953-5958.
18. + in intestinal adenomas from Min mice. Cancer Res. 54:1994;5947-5952.
19. Mahmoud N.N., Boolbol S.K., Bilinski R.T., Martucci C., Chadburn A., Bertagnolli M.M. Apc gene mutation is associated with a dominant-negative effect upon intestinal cell migration. Cancer Res. 57:1997;5045-5050.
20. Mahmoud N.N., Boolbol S.K., Dannenberg A.J., Mestre J.R., Bilinski R.T., Martucci C., Newmark H.L., Chadburn A., Bergagnolli M.M. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis. 19:1998;87-91.
21. Mahmoud N.N., Dannenberg A.J., Mestre J.R., Bilinski R.T., Churchill M., Martucci C., Newmark H., Bertagnolli M.M. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery. 124:1998;225-231.
22. Mahmoud N.N., Bilinski R.T., Churchhill M.R., Edelmann W., Kucherlapati R., Bergagnolli M.M. Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac. Cancer Res. 59:1999;353-359.
23. Mahmoud N.N., Dannenberg A.J., Bilinski R.T., Mestre J.R., Chadburn A., Churchill M., Martucci C., Bertagnolli M.M. Administration of an unconjugated bile acid increases duodenal tumors in a murine model of familial adenomatous polyposis. Carcinogenesis. 20:1999;299-303.
24. McCormick D.L., Johnsen W.D., Rao K.N.V., Bowman-Gram T., Steele V.E., Lubet R.A., Kelloff G.J. Comparative activity of N-(4-hydroxyphenyl)all-trans-retinamde and α-difluoromethylornithine as inhibitors of lymphoma induction in PIM transgenic mice. Carcinogenesis. 17:1996;2513-2517.
25. Nakatsugi S., Fukutake M., Takahashi M., Fukuda K., Isoi T., Taniguchi Y., Sugimura T., Wakabayashi K. Suppression of intestinal polyp development by nimesulfide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn. J. Cancer Res. 88:1997;1117-1120.
26. Oshima M., Oshima H., Kitagawa K., Kobayashi M., Itakura C., Taketo M. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc. Natl. Acad. Sci. 92:1995;4482-4486.
27. Δ716 knockout mice. Carcinogenesis. 16:1995;2605-2607.
28. Oshima M., Oshima H., Tsutsumi M., Nishimura S., Sugimura T., Nagao M., Taketo M.M. Effects of 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine on intestinal polyp development in Apc delta 716 knockout mice. Mol. Carcinogen. 15:1996;11-17.
29. Paulsen J.E., Elvasaas I.-K., Steffensen I.-L., Alexander J. A fish oil derived concentrate enriched in eicosapentaenoic and docosahexaenoic acid as ethyl esters suppresses the formation and growth of intestinal polyps in the Min mouse. Carcinogenesis. 18:1997;1905-1910.
30. Paulsen J.E., Stamm T., Alexander J. A fish oil derived concentrate enriched in eicosapentaenoic and docosahexaenoic acid as ethyl esters inhibits the formation and growth of aberrant crypt foci in rat colon. Pharmacol. Toxicol. 82:1998;28-33.
31. Paulsen J.E., Steffensen I.-L., Andreassen Å., Vikse R., Alexander J. Neonatal exposure to the food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine via breast milk or directly induces intestinal tumors in multiple intestinal neoplasia mice. Carcinogenesis. 20:1999;1277-1282.
32. Perkins S.N., Hursting S.D., Haines D.C., James S.J., Miller B.J., Phang J.M. Chemoprevention of spontaneous tumorigenesis in nullizygous and p53-deficient mice by dehydroepiandrosterone and its analog 16alpha-fluoro-5-androsten-17-one. Carcinogenesis. 18:1997;989-994.
33. Pierre F., Perrin P., Champ M., Bornet F., Meflah K., Menanteau J. Short-chain fructo-oligosaccharides reduce the occurance of colon tumors and develop gut-associated lumphoid tissue in Min mice. Cancer Res. 57:1997;225-228.
34. Polakis P. The oncogenic activation of β-catenin. Curr. Opin. Cell. Biol. 9:1999;15-21.
35. Quesada C.F., Kimata H., Mori M., Nishimura M., Tsuneyoshi T., Baba S. Piroxicam and acarbose as chemopreventive agents for spontaneous intestinal adenomas in APC gene 1309 knockout mice. Jpn. J. Cancer Res. 89:1998;392-396.
36. Ritland S.R., Gendler S.J. Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis. 20:1999;51-58.
37. Smalley W.E., DuBois R.N. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv. Phramacol. 39:1997;1-20.
38. Smits R., Kielman M.F., Breukel C., Zurcker C., Neufeld K., Jamohan-Changur S., Hofland N., van Dijk J., White R., Edelmann W., Kucherlapati R., Khan P.M., Fodde R. Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development. Genes Dev. 13:1999;1309-1321.
39. Steffensen I.-L., Paulsen J.E., Eide T.J., Alexander J. 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine increases the numbers of tumors, cystic crypts and aberrant crypt foci in multiple intestinal neoplasia mice. Carcinogenesis. 18:1997;1049-1054.
40. Storer R.D., Cartwright M.E., Cook W.O., Soper K.A., Nichols W.W. Short-term carcinogenesis bioassay of genotoxic procarcinogens in PIM transgenic mice. Carcinogenesis. 16:1995;285-293.
41. Sørensen I.K., Mortensen A., Kristiansen E., van Kreijl C., Adamson R.H., Thorgeirsson S.S. Short-term carcinogenicity testing of 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP), in and 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) in E(mu)-pim-1 transgenic mice. Carcinogenesis. 17:1996;2221-2227.
42. Sørensen I.K., Kristiansen E., Mortensen A., van Kranen H., van Kreijl C., Fodde R., Thorgeirsson S.S. Short-term carcinogenicity testing of a potent murine intestinal mutagen, 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP), in Apc1638N transgenic mice. Carcinogenesis. 18:1997;777-781.
43. Sørensen I.K., Kristiansen E., Mortensen A., Nicolaisen G.M., Wijnands J.A., van Kranen H.J., van Kreijl C.F. The effects of soy isoflavones on the development of intestinal neoplasia in ApcMin mouse. Cancer Lett. 130:1998;217-225.
44. Ushida Y., Sekine K., Kuhara T., Takasuka N., Iigo M., Tsuda A. Inhibitory effects of lactoferrin on intestinal polyposis in the Apc (Min) mouse. Cancer Lett. 143:1998;141-145.
45. van Kranen H.J., van Iersel P.W.C., Rijnkels J.M., Beems D.B., Alink G.M., van Kreijl C.F. Effects of dietary fat and a vegetables-fruit mixture on the development of intestinal neoplasia in the ApcMin mouse. Carcinogenesis. 19:1998;1597-1601.
46. Wasan H., Novelli M., Bee J., Bodmer W. Dietary fat influences on polyp phenotype in multiple intestinal neoplasia mice. Proc. Natl. Acad. Sci. 94:1997;3308-3313.
47. Williamson S.L.H., Kartheuser A., Coaker J., Kooshkghazi M.D., Fodde R., Burn J., Mathers J.C. Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 month. Carcinogenesis. 20:1999;805-810.
48. Yang K., Edelmann W., Fan K., Lau K., Leung D., Newmark H., Kucherlapati R., Lipkin M. Dietary modulation of carcinoma development in a mouse model for human familial adenomatous polyposis. Cancer Res. 58:1998;5713-5717.
49. Yang K., Fan K., Shinozaki H., Newmark H., Edelmann W., Kucherlapati R., Lipkin M. Sulindac increases carcinoma development in colons of mice with Apc mutations. Proc. Am. Assoc. Cancer Res. 40:1999;529.